Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mdq207
复制
发表时间：
2010-05-01
影响因子：
50.5
通讯作者：
Felip, E.
中科院分区：
文献类型：
--
作者：
Crino, L.;Weder, W.;Felip, E.
提高肺癌的生存率是现代肿瘤学面临的主要挑战，因为在所有疾病阶段，5年生存率仍然< 15%，诊断后10年生存率< 7%。由于局部晚期和转移性非小细胞肺癌（NSCLC）的生存率难以显著提高，从无病生存和总生存的角度来看，早期诊断和治疗在理论上代表了改变NSCLC预后的最一致的可能性。
Improving survival in lung cancer is a major challenge for modern oncology considering that 5-year survival remains< 15%, across all stages of disease and with< 7% of patients alive 10 years after diagnosis.Because of the difficulties in significantly improving survival in locally advanced and metastatic non-small-cell lung cancer (NSCLC), diagnosis and treatment of early stages theoretically represent the most consistent possibility of modifying the outcome of NSCLC in terms of disease-free and overall survival.